Dr. Cowey is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3410 Worth St
Dallas, TX 75246Phone(214) 370-1000
Fax(214) 370-1202- Is this information wrong?
Education & Training
University of North Carolina HospitalsFellowship, Hematology/Oncology, 2006 - 2009
University of Alabama Medical CenterResidency, Internal Medicine, 2003 - 2006
University of Texas Medical BranchClass of 2003
Certifications & Licensure
TX State Medical License 2009 - 2022
AL State Medical License 2005 - 2006- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Molecularly Targeted Therapy in Treating Patients With Melanoma That is Metastatic or Cannot be Removed by Surgery Start of enrollment: 2014 May 01Bryce, A.H.,Cowey, C.L.,Lao, C.D.,Zuccaro, C.,Schwartz, G.K.,Tawbi, H.A.,Sosman, J.A.,Forman, K.,Fecher, L.A.,LoRusso, P.,Chapman, P.B.,Joseph, R.W.,Ejadi, S.,Markovic, S.N.
- A Phase III Randomized, 3-arm, Open Label, Multicenter Study of LGX818 Plus MEK162 and LGX818 Monotherapy Compared With Vemurafenib in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma Start of enrollment: 2013 Sep 01Feun, L.G.,Cosgriff, T.M.,Packer, S.H.,Panella, T.J.,Garrison, M.,O'Day, S.J.,Niederman, T.M.,Wender, D.B.,Pecora, A.L.,Mazurczak, M.A.,Spira, A.I.,Beck, J.M.,Slater, D.,Starodub, A.N.,Hauke, R.J.,Tarhini...
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 01Butler, T.,Beck, J.T.,O'Day, S.,Wong, M.K.,Minor, D.,Sikic, B.,Atkins, M.,Wright, D.D.,Reeves, J.,Hallmeyer, S.,Starodub, A.N.,Berg, S.E.,Kumar, P.P.,Flaherty, K.T.,Flaherty, L.,Gribbin, T.,Rudrapatna, V....
Publications & Presentations
PubMed
- An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 ...Cowey, C. L., Boyd, M., Aguilar, K. M., Beeks, A., Krepler, C., Scherrer, E.> ;Cancer medicine. 2020 Sep 2
- Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma.Hamid, O., Cowey, C. L., Offner, M., Faries, M., Carvajal, R. D.> ;Cancers. 2019 Oct 28
- A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.Ott, P. A.,Pavlick, A. C.,Johnson, D. B.,Hart, L. L.,Infante, J. R.,Luke, J. J.,Lutzky, J.,Rothschild, N. E.,Spitler, L. E.,Cowey, C. L.,Alizadeh, A. R.,Salama, A. K.,...> ;Cancer. 2019 Jan 29
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Baylor University Medical CenterDallas, Texas
Medical City DallasDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
